About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Med13tm1Eno
targeted mutation 1, Eric N Olson
MGI:5431516
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Med13tm1Eno/Med13tm1Eno
Tg(Myh6-cre)2182Mds/0 		involves: 129 * C57BL/6 * FVB/N MGI:5431523
cn2
 		Med13tm1Eno/Med13tm1Eno
Med13ltm1a(KOMP)Wtsi/Med13ltm1a(KOMP)Wtsi
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+ 		involves: 129 * C57BL/6N * FVB/N MGI:8297409


Genotype
MGI:5431523
cn1
Allelic
Composition		 Med13tm1Eno/Med13tm1Eno
Tg(Myh6-cre)2182Mds/0
Genetic
Background		 involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Med13tm1Eno mutation (0 available); any Med13 mutation (89 available)
Tg(Myh6-cre)2182Mds mutation (3 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
homeostasis/metabolism
increased susceptibility to diet-induced obesity ( J:186193 )
• in mice fed a high fat diet
increased circulating insulin level ( J:186193 )
• in mice fed a high fat diet
increased circulating leptin level ( J:186193 )
• in mice fed a high fat diet
increased circulating cholesterol level ( J:186193 )
• in mice fed a high fat diet
increased circulating triglyceride level ( J:186193 )
• in mice fed a high fat diet
impaired glucose tolerance ( J:186193 )
• in mice fed a high fat diet
increased liver triglyceride level ( J:186193 )
• in mice fed a high fat diet

adipose tissue
increased brown adipose tissue amount ( J:186193 )
• increased subscapular fat pad in mice fed a high fat diet
increased abdominal adipose tissue amount ( J:186193 )
• mice fed a high fat diet exhibit increased visceral white adipose tissue compared with wild-type mice
increased total body fat amount ( J:186193 )
• dramatic in mice fed a high fat diet
increased white fat cell size ( J:186193 )
• in mice fed a high fat diet

growth/size/body
increased lean body mass ( J:186193 )
• small in mice fed a high fat diet
increased body weight ( J:186193 )
• in mice fed a high fat diet
increased susceptibility to diet-induced obesity ( J:186193 )
• in mice fed a high fat diet
increased liver weight ( J:186193 )
• in mice fed a high fat diet

cardiovascular system
cardiovascular system phenotype ( J:186193 )
N
• mice exhibit normal cardiac morphology and physiology

liver/biliary system
increased liver weight ( J:186193 )
• in mice fed a high fat diet
increased liver triglyceride level ( J:186193 )
• in mice fed a high fat diet




Genotype
MGI:8297409
cn2
Allelic
Composition		 Med13tm1Eno/Med13tm1Eno
Med13ltm1a(KOMP)Wtsi/Med13ltm1a(KOMP)Wtsi
A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+
Genetic
Background		 involves: 129 * C57BL/6N * FVB/N
Cell Lines EPD0207_6_B04
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
A1cfTg(Myh6-cre/Esr1*)1Jmk mutation (5 available); any A1cf mutation (37 available)
Med13ltm1a(KOMP)Wtsi mutation (1 available); any Med13l mutation (118 available)
Med13tm1Eno mutation (0 available); any Med13 mutation (89 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:376346 )
• median survival time is 6 weeks from the start of tamoxifen administration, with 100% mortality observed at 10 weeks after tamoxifen treatment

cardiovascular system
enlarged heart ( J:376346 )
• at 4 weeks after tamoxifen treatment, volume-to-mass ratio is increased by ~0.68 uL/mg
increased heart weight ( J:376346 )
• at 4 weeks after tamoxifen treatment, heart weight-to-body weight ratio is increased by ~2.9 mg/g
cardiac fibrosis ( J:376346 )
• at 4 weeks after tamoxifen treatment, mice develop cardiac fibrosis as revealed by Massons trichrome staining; qRT-PCR analysis indicates significant upregulation of the pro-fibrotic markers Col1a1, Col3a1, Tgfb1
dilated cardiomyopathy ( J:376346 )
• at 4 weeks after tamoxifen treatment, mice exhibit basal cardiac dysfunction consistent with heart failure
• however, H&E staining shows no major cardiac structural abnormalities
decreased heart ventricle muscle contractility ( J:376346 )
• at 4 weeks after tamoxifen treatment, echocardiography shows a ~50% reduction in ejection fraction in both sexes, along with an ~69 uL increase in end diastolic volume and an ~66 uL increase in end systolic volume
• however, no difference is observed in the heart rate relative to controls
congestive heart failure ( J:376346 )
• at 4 weeks after tamoxifen treatment, mice exhibit lethal heart failure

muscle
dilated cardiomyopathy ( J:376346 )
• at 4 weeks after tamoxifen treatment, mice exhibit basal cardiac dysfunction consistent with heart failure
• however, H&E staining shows no major cardiac structural abnormalities
decreased heart ventricle muscle contractility ( J:376346 )
• at 4 weeks after tamoxifen treatment, echocardiography shows a ~50% reduction in ejection fraction in both sexes, along with an ~69 uL increase in end diastolic volume and an ~66 uL increase in end systolic volume
• however, no difference is observed in the heart rate relative to controls

growth/size/body
enlarged heart ( J:376346 )
• at 4 weeks after tamoxifen treatment, volume-to-mass ratio is increased by ~0.68 uL/mg
increased heart weight ( J:376346 )
• at 4 weeks after tamoxifen treatment, heart weight-to-body weight ratio is increased by ~2.9 mg/g




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
01/28/2026
MGI 6.24 		The Jackson Laboratory